Implications of Human Papillomavirus Infections in the Biology of Head and Neck Cancers by Descamps Géraldine et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Implications of Human Papillomavirus 
Infections in the Biology of 
 Head and Neck Cancers  
Descamps Géraldine1, Duray Anaëlle1, 
 Delvenne Philippe2 and Saussez Sven1 
1Laboratory of Anatomy, Faculty of Medicine and Pharmacy, 
 University of Mons 
2Department of Pathology, CHU Sart-Tilman, University of Liège  
Belgium 
1. Introduction 
1.1 Epidemiology 
Head and neck squamous cell carcinomas (HNSCCs) remain a significant cause of 
morbidity worldwide, with as many as 466831 and 168368 cases diagnosed in 2008 among 
men and women, respectively (Globocan, 2008; Grandis et al., 2004; Shah et al., 2003). 
HNSCCs constitute a collection of diseases that, despite their shared location and histology, 
can become different types of tumors that differ in pathogenesis, biology, sub-location and 
treatment and that can affect quality of life, including survival (Grandis et al., 2004; Shah et 
al., 2003). HNSCC patients in the early clinical stages (stages I and II) have similar survival 
rates, with a five-year survival between 70 and 90%, independent of the sub-location 
(Forastiere & Trotti, 1999). In contrast, HNSCC patients in the advanced clinical stages 
(stages III and IV) display completely different survival rates depending on the histological 
type of the tumor and its sub-location (Denis et al., 2004; Forastiere & Trotti, 1999). In 2008, 
Globocan data indicated that HNSCCs constituted the sixth and eighth most frequent cancer 
among men and women, respectively. Their frequency has varied over the last 20 years, 
with an increasing prevalence in women, which is highest in Europe, and a decreasing 
prevalence in men, which is highest in the USA. A comparison of global statistics with 
official data from Belgium reveals a strikingly increased incidence of HNSCCs in both sexes, 
with important regional differences. Indeed, Belgium has a higher incidence of HNSCC 
associated with smoking and alcohol consumption compared with other countries. In 2005, 
HNSCCs were the fourth most common cancer in men after prostate, lung and colorectal 
cancers and the eighth most common cancer in women after breast, colorectal, uterine, lung, 
melanoma, ovarian cancers and non-Hodgkin’s lymphoma (Filleul et al., 2011). We can also 
observe inter-regional heterogeneity; in fact, the incidence is higher in men in Wallonia than 
in the Brussels region where the incidence of HNSCC in women rose. Finally, when we 
compare Belgian and French data, these cancers seem more frequent in French men than in 
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Belgian men, but there is an opposite trend among women, in which carcinomas of the 
larynx are more frequent in Belgium than in France.  
1.2 Treatments of HNSCCs 
The treatment of HNSCC patients in advanced disease stages combines surgery, radiation 
oncology, medical oncology, medical imaging and clinical pathology (Denis et al., 2004; 
Forastiere & Trotti, 1999; Grandis et al., 2004; Shah et al., 2003). This type of collaborative 
medical approach was initiated as early as 1970 when Fletcher and Evers reported the first 
convincing evidence showing the benefits of combining radiotherapy with surgery 
(Adelstein et al., 2003). In this context, cisplatin was investigated for the treatment of 
HNSCC in the early 1970s, and, from the late 1970s to the early 1990s, promising results 
were obtained with the use of various combinations of postoperative chemotherapy with 
radiotherapy in randomized (Al-Sarraf et al., 1998) and non-randomized studies (Jeremic et 
al., 2000). In the early 2000s, the Radiation Therapy Oncology Group (Denis et al., 2004) and 
the European Organization for Research and Treatment of Cancer (EORTC) (Cooper et al., 
2004) conducted two randomized studies to test the relative efficacy of concurrent 
postoperative cisplatin administration and radiotherapy in the treatment of HNSCC. These 
two studies demonstrated that local control of the disease was significantly higher in the 
combined therapy group than in the group that received radiotherapy alone. Unfortunately, 
these combined treatments were frequently associated with adverse side effects. Although 
significant progress has been observed after combined treatments, a number of statements 
concerning HNSCCs currently remain valid: (i) almost two-thirds of HNSCC patients have 
advanced forms (stages III and IV) of the disease at diagnosis, (ii) 50% of HNSCC patients 
die within the two years following the initial diagnosis, and (iii) every year, 5% of the 
patients develop additional primary tumors. Therefore, novel approaches seem to be 
required to provide head and neck oncologists with a more effective armamentarium 
against this challenging disease (Bernier et al., 2004; Lang et al., 2004).  
1.3 Risk factors for the development of HNSCC 
Tobacco use and alcohol consumption are now well-established risk factors for the 
development of HNSCC; however, a proportion of HNSCC patients (15–20%) develop 
tumors even in the absence of exposure to these agents (Gillison et al., 2000) Moreover, 
Sturgis and Cinciripini reported that the overall incidence of HNSCC has declined in the 
United States over the past 20 years, which has been attributed to a decrease in smoking. 
Nevertheless, the study also demonstrated an increase in the frequency of tongue and 
pharyngeal cancers (Sturgis & Cinciripini, 2007). These findings suggest the importance of 
other risk factors, such as human papillomavirus (HPV), in the development of 
oropharyngeal and oral carcinomas.  
2. HNSCC and HPV: incidence, biological pathways and impact on prognosis  
Currently, persistent high-risk HPV (hr HPV) infection is widely accepted as the major 
cause of uterine cervical carcinoma with HPV 16 and 18 being the two most implicated 
types. These oncogenic papillomaviruses have also been related to others lesions, such as 
vulvar, vaginal, penile, anal and more recently, head and neck squamous cell carcinomas 
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(Chung & Gillison, 2009). Since 1983 when Syrjänen published the first study analyzing 
HPV infection in HNSCCs, the etiological role of HPV has become increasingly accepted. 
Indeed, although tobacco and alcohol exposure are established risk factors for HNSCCs, 
HPV infection may act synergistically with these carcinogenic agents. Presently, more than 
120 human papillomaviruses have been identified by complete DNA sequence analysis. 
They are classified by family, genus, species and types according to several criteria. More 
precisely, types are determined on the basis of sequence homology to the gene encoding the 
L1 protein, which is the most conserved gene in the HPV genome (Aubin et al., 2007; de 
Villiers et al., 2004; de Villiers & Gunst, 2009). The genotypes are also more commonly used 
to refer the different types. However, in clinical practice, distinctions between HPV types 
include the type of epithelium infected (cutaneous vs. mucosal HPV) and the ability to effect 
cellular transformation. The capacity to transform epithelial cells is divided into high risk 
and low risk HPV: a benign proliferation is associated with the low-risk (lr) HPV type, and 
malignancy is associated with the high-risk (hr) HPV type (Nebesio et al., 2001; Syrjänen et 
al., 2011).  
The human papillomavirus belongs to the highly diverse Papillomaviridae family. The HPV 
virion has a diameter of 55 nm and consists of circular double-stranded DNA containing 
approximately 8000 base pairs (bp). The HPV genome is encapsulated in a proteic capsid of 
72 capsomers. Notably, the lack of envelope makes this virus resistant to environmental 
conditions, infectious for years and resistant to many therapeutics agents. The HPV genome 
consists of three major regions. The non-coding long control region (LCR) of 1000 bp 
contains the p97 promoter controlling E6 and E7 transcription, transcriptional regulatory 
elements and the binding sites for the E2 and E1 gene products (Neufcoeur et al., 2009; 
Ragin et al., 2007). The 3000bp region encodes two structural capsid proteins, namely, the 
late proteins L1 and L2. The icosahedral capsid can be constituted of L1 proteins alone or 
together with L2. The L1 capsid is comprised of 360 L1 molecules assembled as 72 
pentameric capsomers, and the L1-L2 capsid contains 12 additional L2 molecules (Ishii et al., 
2005). The six early proteins are encoded by a 4000bp region: two of the early proteins, E1 
and E2, are regulatory proteins that modulate the replication and transcription of viral DNA 
and the expression of the other early genes; the early protein E4 acts in association with 
keratin filaments in host epithelial cells; the remaining three early proteins, E5, E6, and E7, 
are oncogenes involved in cellular transformation and maintenance of the malignant 
phenotype (Chung & Gillison, 2009; Doorbar & Myers, 1996).  
2.1 Life cycle of the human papillomaviruses and molecular mechanisms of head and 
neck HPV carcinogenesis 
The HPV life cycle is particularly complex. HPV infection requires abrasion in the stratified 
epithelium, providing access to the basal layer. Attachment of the virus to the host cell may be 
achieved through cell surface receptors or glycosaminoglycans, such as heparin sulfate. After 
this attachment, virions can be internalized via clathrin-dependent endocytosis and, after 
uncoating, the viral DNA is transported into the nucleus by the cytoskeleton. During this early 
infection, the virus maintains its genome as a nuclear episome at a low copy number (10-200 
copies per cell) in the basal cell of the epithelium. This slight proliferation is limited in the basal 
cell layers, due to the expression of E1 and E2 proteins, which maintain the viral DNA as an 
episome (Chung & Gillison, 2009; Doorbar, 2005; Monsonégo, 2007). E1 is an ATP-dependent 
helicase initiating the viral replication in cooperation with E2 (Hughes & Romanos, 1993). 
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Moreover, E2 can act as a transcriptional repressor of E6 and E7 expression by binding to the 
non-coding region LCR, and it has a crucial role in the segregation of the viral genome during 
cell division (Psyrri & Dimaio, 2008; You et al., 2004). This initial infection is followed by a 
proliferative phase corresponding to an increased number of viral episomes. Indeed, normal 
epithelial cells differentiate from the basement membrane toward the apical surface. During 
this proliferative phase, the HPV genome may remain episomal or become integrated into the 
host genome. Next, the HPV DNA replicates to a high copy number and is encapsidated to 
produce virions only in terminally differentiated epithelial cells. Integration of the HPV 
genome into the host chromosome is thought to be a late event and to occur at random with a 
predilection for fragile chromosomal sites. This integration also leads to the loss of the E1 and 
E2 genomic sequences, releasing the HPV oncogenes from repression (Ragin et al., 2007). 
Overexpression of both E6 and E7 stimulate cell cycle progression with S-phase entry, leading 
to proliferation of squamous epithelial cells of the upper aerodigestive tract. These two 
oncogenes alter key tumor suppressor pathways. The third oncogene, E5, exerts its 
carcinogenic effects only during the early stages of infection because its gene sequence is 
deleted when HPV integrates the host genome (zur Hausen & de Villiers, 1994). However, this 
protein stimulates cell growth through binding to the epidermal growth factor receptor 
(EGFR), initiating cascades leading to upregulation of proto-oncogenes. The association of E7 
with the retinoblastoma protein (pRb) is now well characterized. The pRb protein is a negative 
regulator of the cell cycle that prevents S-phase entry under normal conditions by associating 
with the E2F transcription factor. The association between pRb and E2F is broken upon HPV 
infection: E7 binds to pRb, leading to its degradation and the subsequent release of E2F, which 
stimulates cell proliferation. Note that the inactivation of pRb results in a reciprocal 
overexpression of the p16 protein, which is an inhibitor of cyclin-dependent kinases. Indeed, 
the Rb gene also regulates p16 by a negative feedback mechanism; consequently, the 
inactivation of pRb leads to p16 upregulation. The expression of this protein is elsewhere 
considered as a surrogate marker for HPV infection in both cervical and head and neck cancer 
(Klozar et al., 2010; Li et al., 1994). The E6 protein of hr HPVs binds simultaneously to a 
cellular ubiquitin ligase, known as the E6-associated protein (E6-AP), and to the tumor 
suppressor protein p53, resulting in its ubiquitination and subsequent proteolytic degradation. 
Normally, p53 regulates growth arrest and apoptosis after DNA damage and, depending on 
the damage incurred; p53 induces a prolonged cell cycle arrest or triggers apoptosis. 
Moreover, HPV infected cells avoid this process of cell death by E6-mediated inactivation of 
p53. This oncogene interferes with other pro-apoptotic proteins of both extrinsic and intrinsic 
apoptotic pathways, such as Bak, FADD and pro-caspase 8 (Garnett et al., 2006; Narisawa-saito 
& Kiyono, 2007; Thomas & Bank, 1999). Thus, these two oncoproteins are essential factors for 
HPV-induced cellular immortalization, transformation and carcinogenesis. Finally, expression 
of the late proteins L1 and L2 occurs in the upper layer, as cells differentiate and allow the 
encapsidation of the genome and the production of new infectious virions, which are released 
into the extracellular environment to re-initiate infection.  
2.2 Epidemiology and incidence of HPV infection in head and neck region 
In recent years, the relation between the presence of HPV DNA and the development of head 
and neck tumors from different anatomical sites was analyzed. Differences in prevalence were 
found from one site to another. For example, the meta-analysis directed by Kreimer considered 
more than 5000 tumors from 60 studies conducted on five continents; the authors showed that 
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oropharyngeal tumors had the highest HPV prevalence (35.6%). Oral and laryngeal (including 
hypopharyngeal) carcinomas were infected in 23.5% and 24% of cases, respectively (Kreimer et 
al., 2005). Note that HPV16 accounted for 86.7% of all HPV-positive oropharyngeal tumors, 
compared with 68.2% in oral and 69.2% in laryngeal squamous cell carcinomas. Recently, Laco 
and colleagues also demonstrated this higher proportion in their study: 24 oral SCCs and 22 
oropharyngeal SCCs (OPSCCs) were analyzed for HPV presence using the polymerase chain 
reaction (PCR). The results indicated that 82% of OPSCCs were HPV-positive, compared with 
13% of OSCCs (Laco et al., 2011). The biological explanation for this higher HPV prevalence in 
tumors arising in oropharynx is becoming clearer. Both the tonsils and the base of tongue are 
lymphoid tissues that produce cytokines, which may affect HPV transcription and promote 
cell transformation (Klussmann et al., 2001). Furthermore, the tonsil epithelium presents 
morphological similarities to those of genital epithelia, such as deep invaginations of the tonsil 
surface that may facilitate viral particle retention. These invaginations, also called crypts, are 
flanked by stratified squamous epithelium, which facilitate viral access to basal cells. 
Additionally, both genital and tonsillar epithelia derive from the same endodermal embryonic 
layer (Ernoux et al., 2009).  
As previously mentioned, reported rates of HPV positivity in HNSCCs vary widely. This 
inconsistency will be discussed with respect to anatomical site in a later chapter. However, 
this widespread variability must be interpreted with caution, but may be partially explained 
notably by differences in methodology of HPV detection. Indeed, according to several 
studies, multiple HPV detection methods are used, such as the polymerase chain reaction 
(PCR), in situ hybridization (ISH) and Southern hybridization. Among these techniques, 
numerous studies agree that PCR is the most sensitive. In fact, a review of the literature by 
Miller and White showed that HPV was identified with a higher frequency by using PCR 
(37.1%) than by using moderate- or low-sensitivity assays, such as Southern hybridization 
(27.2%) or ISH and immunohistochemistry (25.2%) (Miller & White, 1996). However, despite 
an increase in the use of PCR to detect HPV, variability in prevalence still exists and may be 
attributed to differences in the sensitivity of the PCR primer sets. Different consensus primer 
sets are used to detect and amplify HPV DNA, but the two most frequently used are the 
GP5+/GP6+ and the MY09/11 primers. Moreover, it seems that GP5+/GP6+ primers are 
more sensitive than MY09/11 for HPV detection in oral samples. Remmerbarch also 
recommends the PCR approach with nested GP5+/GP6+ primers (Remmerbach et al., 2004). 
Other explanations for the varying rates of prevalence could be the sample sources and 
collection methods (scalpel biopsy, swabs, brushings, and mouthwash). The geographical 
locations of the studies may also contribute to variations in HPV prevalence. Indeed, HPV 
prevalence in OSCCs is similar in Europe (16%) and North America (16.1%) but significantly 
greater in Asia (33%). For OPSCCs, the prevalence is significantly higher in North America 
(47%) compared with Europe (28.2%) (Kreimer et al., 2005). Finally, patient profiles, such as 
smokers vs. non-smokers and/or drinkers vs. non-drinkers, could also contribute to some 
variations. It turns out that the literature presents conflicting accounts of the association 
between smoking and/or drinking and HPV in the development of HNSCCs. Indeed, we 
can distinguish three distinct categories: studies showing that HPV is clearly associated with 
an increased risk of HNSCC in non-smokers, studies finding no difference in HPV-related 
carcinoma between smokers and non-smokers and studies providing evidence of an 
additive or synergistic effect between smoking and HPV-related HNSCC (Sinha et al., 2011). 
Fouret observed a higher prevalence of HPV in non-smokers, while an additive interaction 
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was observed by Smith. HPV-positive smokers presented a greater risk of HNSCC 
compared with HPV-negative smokers or HPV-positive non-smokers (Fouret et al., 1997; 
Smith et al., 2004a). On the other hand, Paz found no statistical association between tumor 
HPV status and tobacco use (Paz et al., 1997). Biologically, smoking and alcohol can cause 
cellular and structural modifications in oral epithelia, which potentially increase the 
permeability to viral infection. These environmental agents are also known to suppress 
mediators of immune functions, facilitating HPV infection persistence (Pannone et al., 2011; 
Ragin et al., 2007; Sinha et al., 2011).  
2.3 Prognosis of HPV positive head and neck squamous cell carcinoma 
The significance of hr HPV infection and its impact on patient prognosis remains an 
important matter of debate, although a majority of studies have now confirmed an 
improved survival of HPV-positive patients compared with HPV-negative patients (Fakhry 
et al., 2008; Lindel et al., 2001; Lindquist et al., 2007). However, this strong positive 
prognostic factor is often confirmed in tonsillar and oropharyngeal carcinomas. Notably, the 
majority of studies that demonstrated increased survival were reporting on patients with 
oropharyngeal and/or tonsillar tumors (Ang et al., 2010; Lindel et al., 2001; Sedaghat et al., 
2009). The meta-analysis by Ragin et al. examining the relationship between HPV and 
overall survival did not show any survival differences between HPV-positive and HPV-
negative patients with cancer in non-oropharyngeal sites (Ragin et al., 2007). The same 
observation was made by Gillison et al., suggesting that these tumors may have an etiology 
distinct from that of tumors in non-oropharyngeal sites (Gillison et al., 2000). In fact, this 
subset of oropharyngeal HPV-positive cancers possesses distinct clinical features and 
outcomes, and it is particularly common in individuals who lack the traditional risk factors 
of tobacco and alcohol abuse. While it is unclear whether tobacco is a risk factor for HPV-
induced oropharyngeal tumors, it seems that smoking has a negative impact on the survival 
of patients with HPV-positive tumors (Hafkamp et al., 2008). Nevertheless, there are reports 
in the literature on the prognostic significance of HPV infection describing a reduced 
influence on prognosis and other reports demonstrating no influence on prognosis. Indeed, 
two Swedish studies demonstrated that oral HPV infection was associated with a 
dramatically increased risk of OSCC development (Hansson et al., 2005; Rosenquist et al., 
2007). Additionally, in 1994, Clayman et al. also showed that HPV detection significantly 
correlated with decreased survival (Clayman et al., 1994). On the other hand, other studies 
have failed to demonstrate an association between HPV positivity and prognosis (Duray et 
al., 2011a; Ernoux et al., 2011; Koskinen et al., 2003; Morshed et al., 2010). From a biological 
point of view, it is difficult to explain why patients with HPV infections have a worse 
survival than HPV-negative patients. One possible explanation is that HPV infected cells in 
locations with inflammatory activity may be stimulated to divide, facilitating tumor 
development (Dahlgren et al., 2004). Another hypothesis is that immunosuppression may 
favor HPV infection (Duray et al, 2010). In 2004, Kreimer reported that tonsillar HPV 
infection was strongly associated with HIV co-infection and immunosuppression (Kreimer 
et al., 2004). Recently, herpes simplex virus-2 (HSV2) infection was demonstrated to increase 
the risk of HPV infection (Moscicki et al., 2001). Furthermore, a study performed by Tung et 
al. reported the presence of HPV-16 or -18 and Epstein-Barr virus (EBV) in 80% of 
nasopharyngeal carcinoma samples (Tung et al., 1999). These co-infections might play an 
important role in the initiation of neoplastic transformation in human oral epithelial cells. 
HPV infections have also been implicated in several tumor cell immune escape mechanisms, 
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such as the absence of an inflammatory response against tumor cells, the production of 
regulatory cytokines and the downregulation of Toll-like receptor 9 (Lepique et al., 2009). 
3. HPV related head and neck carcinomas versus HPV non-related head and 
neck carcinomas: two different tumor entities 
Head and neck tumors are now defined as two separate clinical entities: HPV-positive 
tumors and HPV-negative tumors. The tumors differ both clinically and molecularly. HPV-
positive tumors present distinct histopathological features, including notably non-
keratinizing basal cells and a prominent “koilocytic” morphology. These features were also 
associated with a basaloid morphology that is a morphologic variant of HNSCC (Williams et 
al., 1996). These HPV-positive tumors are also known to occur in a younger age group, to 
originate more frequently in the oropharynx (especially in the palatine tonsils and at the 
base of tongue), to be poorly differentiated because patients present with later-stage disease 
and to have a lower T-stage than HPV-negative tumors (Marur & Forastière, 2008). Another 
particularity concerns the overall survival, which seems to be better for HPV-infected 
patients. Indeed, the majority of studies agree with that of Gillison and colleagues, who 
found that the risk of dying from disease was reduced in patients with HPV-positive 
HNSCC (Gillison et al., 2000). HPV-positive and HPV-negative tumors also exhibit 
differences in tumor biology with HPV-positive tumors having fewer p53 mutations and 
displaying reduced association with tobacco and alcohol consumption. In fact, 
approximately one-third of the tumors harbor p53 mutations, but a marked difference in p53 
mutation frequency is generally found when comparing HPV-positive and HPV-negative 
oropharyngeal tumors. Thus, this inverse association between p53 mutations and HPV 
detection in the oropharynx further suggests that HPV-positive and HPV-negative HNSCCs 
should be considered to be two distinct cancers with two parallel pathways: one driven by 
environmental agents (tobacco and alcohol) and another driven by infectious agents (high-
risk HPVs). However, these two pathologic agents may interact and act synergistically to 
lead to the development of HNSCCs. All these observations frequently focus on the 
oropharynx, strengthening the etiologic role of HPV in oropharyngeal carcinomas. 
Nevertheless, the implication of HPV in non-oropharyngeal tumors is less firmly established 
(Gillison et al., 2000). Indeed, among HNSCC biopsies, the real HPV prevalence remains 
uncertain, due to the varying incidence rates reported in different studies.  
4. Incidence of HPV in the general population and modalities of transmission 
HPV infection of the oral cavity has not been studied extensively. In fact, the majority of 
studies on the oral and oropharyngeal cavities considered patients with benign or malignant 
lesions and did not include healthy patients. However, to establish the etiology and 
pathogenesis of HPV-associated lesions, it is important to investigate the prevalence of HPV 
in normal tissues. An overview of the literature describing HPV detection in normal head 
and neck mucosa in children and adults is shown in Table 1.  
4.1 Incidence of HPV in normal oral mucosa 
The prevalence of HPV DNA in normal oral mucosa ranges from 0% to 56.7% in healthy 
adults (Table 1). To date, several studies have also evaluated the presence of HPV infection 
in the healthy oral cavity of children. In fact, it is important to know the prevalence of HPV 
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infections in childhood because HPV infection early in life could represent a risk factor for 
the development of head and neck cancer later in life. A prevalence of HPV infection in the 
oral cavities of children aged 0.3-11.6 years ranging from 0% to 47% has been reported 
(Syrjänen, 2010). The highest HPV prevalence rates by age group are detected before 1 year 
of age; the second peak occurs in adolescents aged 13-20 years (Smith et al., 2004b, 2007, 
2010; Summersgill et al., 2001). According to the age studied, there are variations in the 
prevalence rate. In nasopharyngeal aspirates collected immediately after birth, the detection 
rate of HPV varies from 1.5% to 37% (Cason et al., 1995; Castellsague et al., 2009; Mazzatenta 
et al., 1996; Puranen et al., 1996, 1997; Rintala et al., 2005a, 2005b; Rombaldi et al., 2008; 
Sedlacek et al., 1989; Tenti et al., 1997, 1999; Watts et al., 1998). At the age of 1-4 days, Smith 
et al. in two studies found a low HPV incidence (from 0.9% to 1%) in the buccal swabs of 
neonates, whereas other studies showed a higher prevalence varying from 40% to 56% 
(Cason et al., 1995; Kaye et al., 1994; Pakarian et al., 1994; Tseng et al., 1998; Smith et al., 
1995, 2004b). Similarly, the detection rate of HPV in infants between 6 weeks and 6 months 
after delivery varied between 0% and 62% (Cason et al., 2005; Fredericks et al., 1993; Kaye et 
al., 1994; Pakarian et al., 1994; Watts et al., 1998) and among 3-year-old children varied 
between 10% and 40% (Kojima et al., 2003; Puranen et al., 1996, 1997; Szydlowski et al., 
2004). Mant et al. studied the acquisition and the clearance of HPV in the buccal mucosa of 
4- to 9-year-old children and showed that, during a 30-month follow-up, 63% of 19 initially 
HPV-negative children acquired new HPV16 infection, while 40% of 22 initially HPV-
positive children cleared the virus (Mant et al., 2003). In contrast, the Finnish Family HPV 
study found lower rates, which may be due to the fact that the children were younger and 
the detection method less sensitive. In fact, they found that, during the three-year follow-up, 
42% of the children acquired incident infection, while 11% cleared their infection and 10% 
had persistent oral HPV infection (Rintala et al., 2005a, 2005b).  
4.2 Incidence of HPV in normal tonsil 
Regarding the literature, only a few studies have assessed the presence of HPV DNA in 
normal tonsillar tissues, with HPV detection rates varying from 0% to 24.4% in 
children/adolescents and 0% to 100% in adults (Table 1). In order to understand the 
epidemiology of HPV in the healthy population, we detected HPV in the palatine tonsils of 
children and adults who underwent tonsillectomy (recurrent tonsillitis, n=64) or sleep 
surgery (apnea: n=9; snoring: n=7). Among our series of 80 disease-free tonsils, 12.5% (10 
cases) tested positive for hr HPV types [HPV16 (8 cases), HPV18 (1 case) and HPV31 (1 
case)], 15% (12 cases) were positive for lr HPV types and 72.5% (58 cases) were negative. 
Among the hr HPV-positive tonsils, five were from children/adolescents and five were 
from adults (Duray et al., 2011b). By the end of 2002, Syrjänen compiled several studies from 
the United States, Japan, and Western Europe. In total, he determined an 8.5% (17 of 200) 
HPV positivity rate, either type 16 (12 cases) or type 6/11 (5 cases) (Syrjänen, 2004). A Greek 
study determined the presence of HPV DNA in children. They found 9 of 106 tonsils to be 
HPV-positive, with six cases having HPV-16, two cases having HPV-11 and one case having 
an untyped HPV (Mammas et al., 2006). Another study reported HPV-16 infection in 13 of 
206 tonsils (6.3%) with 11 cases from children or young adults aged less than 25 years (Chen 
et al., 2005). These findings differed from those of several other studies in which low 
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prevalence or no prevalence of oncogenic and non-oncogenic HPV was identified in the 
specimens studied (Brandsma & Abramson, 1989; Ernster et al., 2009; Klingenberg et al., 
2010; Klussmann et al., 2001; Niedobitek et al., 1990; Ribeiro et al., 2006; Sisk et al., 2006; 
Snijders et al., 1992). In these anatomical sites, HPV-6 and -11 and HPV-16 and -18 were the 
most common types of lr and hr HPV, respectively (Table 1). According to the literature, 
prevalence rates of oral HPV in normal individuals vary substantially. It is believed that this 
great variation in HPV prevalence rates found in head and neck studies may be due to 
several factors, including the anatomical site, ethnic and geographical differences, the size of 
the cohorts, the sample collection methods (i.e., biopsy, lavages, scrapes), the materials used 
for testing (i.e., formalin-fixed biopsies, frozen or fresh biopsies, exfoliated fresh cells), and, 
probably most importantly, the HPV detection methods used (PCR, in situ hybridization, 
Southern blot hybridization). For example, using PCR and DNA hybridization techniques, 
the results showed a prevalence ranging from 0% to 81% (Castro et al., 2009; Ribeiro et al., 
2006) in oral mucosa swabs of adults, whereas in biopsies, the rate was less variable with 
detection of HPV in 0% to 55% (Table 1). The disadvantages of oral rinsing and cytological 
scraping or brushing are that they collect superficial epithelial cells and that no additional 
tests were performed for validation (Klingenberg et al., 2010). Moreover, no viruses  
from latent infections in the basal or suprabasal layer cells are removed (Esquenazi et al., 
2010). 
4.3 Modalities of transmission of HPV  
4.3.1 Sexual mode of transmission 
It is now well established that, in the case of cervical cancer, HPV infection is a sexually 
transmitted disease, but little is known about transmission of oral HPV infection in the 
general population. In the literature, the majority of the studies evaluated the prevalence of 
HPV and the risk of sexual transmission in HNSCCs, but few studies tried to determine the 
frequency and the modalities of sexual and nonsexual HPV transmission in other groups, 
such as normal children and adult. In fact, Gillison and colleagues conducted a case-control 
study that compared 100 patients with oropharyngeal SCCs and 200 control patients, and 
they demonstrated that oral HPV infection was strongly associated with oropharyngeal 
carcinoma among patients who did not have the classical risk factors of tobacco and alcohol 
use. Moreover, these authors also demonstrated that a high lifetime number of oral sex or 
vaginal sex partners, engagement in casual sex, an early age at first intercourse, and the 
infrequent use of condoms were all associated with HPV-16-positive oropharyngeal cancer. 
These findings suggest that oral HPV infection is sexually acquired and is involved in the 
carcinogenesis of oropharyngeal cancer (D’Souza et al., 2007). More recently, they 
explored whether these sexual behaviors were associated with oral HPV infection in two 
distinct populations (a control patient population and a population of college-aged men). 
The first population (control group), which was enrolled in two case-control studies 
nested within a prospective cohort with HNSCC, consisted of patients at the Johns 
Hopkins outpatient otolaryngology clinic who were ≥ 18 years of age and had no history 
of cancer. The second population (college-aged men population) included male students 
who were > 17 years (women were excluded because some might have received the HPV 
quadrivalent vaccine). Oral HPV infection was detected in 4.8% of 332 control patients 
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and in 2.9% of 210 college-aged men. Among the control group, the odds of developing 
oral HPV infection were significantly greater with increases in the lifetime number of oral 
or vaginal sex partners, whereas among the college-aged men, the odds of developing oral 
HPV infection were significantly greater with increases in the lifetime number of oral sex 
or open-mouth kissing partners, but not with increases in the lifetime number of vaginal 
sex partners. They concluded that oral HPV infection is sexually acquired and is 
transmitted by behaviors such as oral sex and open-mouth kissing (D’Souza et al., 2009). 
However, Smith et al. examined the prevalence of HPV in a large series of pregnant 
women to evaluate the concordance between infection of the cervix and the oral cavity. 
The lack of concordance in HPV types in either of the mucosal sites in pregnant women, 
between detection in the cervix and oral contact, and between females and males, 
suggests that the transmission of infection by auto-inoculation or by oral-genital sex 
between partners is low, suggesting that a number of issues remain unclear about the 
mechanisms of HPV transmission (Smith et al., 2004c). Another study also showed that 
despite a high frequency of oral-penile contact among young adults, the detection of oral 
HPV was rare, and no association between oral-penile contact and oral HPV infection was 
found (Winer et al. 2003). 
4.3.2 Nonsexual mode of transmission 
In children, the modalities of HPV transmission are difficult to explain. Gutman and 
colleagues described anogenital HPV disease in children after abusive sexual contact 
(Gutman et al., 1993). However, the high incidence of HPV infection observed in healthy 
children indicates that the transmission need not be sexual. To explain these pediatric 
HPV infections, several nonsexual modes of transmission can be proposed, including 
vertical transmission, horizontal transmission and autoinoculation. It can be due to a 
vertical transmission, which is divided into three subtypes depending on the assumed 
time of HPV transmission: (1) peri-conceptual transmission (time around fertilization) 
occurs theoretically via the infected oocyte or spermatozoon. Several studies showed the 
presence of HPV DNA in 8 to 64% of semen samples from asymptomatic men and also in 
seminal plasma and spermatozoa (Syrjänen, 2010). (2) Prenatal transmission (during 
pregnancy) has been proposed by studies reporting HPV DNA in amniotic fluid, placenta 
and cord blood samples. In placental samples, the rate of HPV DNA detection varied from 
0% to 42.5% (Syrjänen, 2010). Rombaldi et al. observed an HPV infection in 23.3% of the 
cases studied and transplacental transmission in 12.2%. A significant correlation was also 
observed between placental HPV and the immunosupressive status of the mother 
(Rombaldi et al., 2008). Furthermore, Sarkola and colleagues found that HPV DNA was 
three times more prevalent among women who had smoked compared with never-
smokers (Sarkola et al., 2008a). In amniotic fluid and cord blood, the prevalence of HPV 
varied from 15% to 65% and 0% to 13.5%, respectively. (3) Perinatal transmission occurs 
during birth and immediately thereafter. HPV transmission may be the result of close 
contacts between the fetus and infected cervical and vaginal cells of the mother during 
delivery. Using DNA sequencing, several authors have shown that the mother is the 
source of infection with evidence of virus transcription in some children (Cason et al., 
1995; Kaye et al., 1996). Vertical transmission was considered when the maternal HPV 
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type matches the HPV type isolated from the newborn/child. In 1989, Sedlacek et al. were 
the first to demonstrate HPV DNA in the nasopharyngeal secretions of infants delivered 
vaginally by mothers with genital HPV infection (Sedlacek et al., 1989). Since then, several 
authors evaluated the rate at which HPV is transmitted from mother to newborn/child, 
but this rate is extremely variable among studies. Medeiros and colleagues proposed the 
first systematic review on vertical HPV transmission, which included 2111 pregnant 
women and their 2113 newborns. They showed that pooled mother-to-child HPV 
transmission was 6.5% and was higher after vaginal delivery than after cesarean section. 
The authors also showed that the combined relative risk of mother-to-child HPV 
transmission was 7.3 (Medeiros et al., 2005). Rombaldi et al. determined the rate of 
maternal HPV transmission using PCR and nested multiple PCR on maternal cervical 
swabs and neonatal nasopharyngeal specimens. They reported that the perinatal 
transmission of HPV DNA occurred in 24.5% of the cases studied (Rombaldi et al., 2009). 
Other studies also suggest that vertical transmission is common, occurring in 40% to 80% 
of cases (Puranen et al., 1996; Rintala et al., 2005b; Tseng et al., 1998). These high rates of 
vertical HPV transmission were not confirmed by several studies, which found that the 
risk of vertical transmission to the oral or genital mucosa of newborns was rare (1-5%) 
(Smith et al., 1995, 2004b, 2010; Syrjänen & Puranen, 2000 Tenti et al., 1999; Watts et al., 
1998). In two previous studies by Smith et al., only one mother/newborn pair was 
concordant for an HPV type, and among 203 infants, two had detectable HPV in oral or 
genital swabs (Smith et al., 1995, 2004b). Studies on persistent HPV infection showed that 
the concordance between mother/newborn infections was maintained between 37% to 
83% at six weeks to six months after birth (Cason et al., 1995; Fredericks et al., 1993; Kaye 
et al., 1996), whereas Rintala et al. found that the prevalence declined to 10% in infants at 
24 months of follow-up. This prospective cohort study assessed the dynamics of HPV 
transmission between parents and infants. They showed that the most common HPV 
profile was hr HPV in all family members, followed by HPV-positive mother-infant pairs, 
whereas HPV-positive father-infant pairs were less frequent. No such independent risk 
could be attributed to subclinical HPV infection in the father, but oral and genital HPV in 
the mother affected the risk of infant HPV (Rintala et al., 2005b). Thus, our results support 
the possibility of vertical transmission during pregnancy or perinatal transmission at the 
time of delivery. In other studies, the non-concordance of type-specific HPV between 
mother and newborn or the presence of oral HPV DNA in young children who were born 
to HPV-negative mothers suggest the existence of other transmission routes, such as the 
horizontal transmission of HPV. In these cases, HPV infection can be transmitted by milk 
during breastfeeding, by siblings via kissing, and by householders and friends via digital 
contacts (Syrjänen, 2010). There is one recent article showing the presence of HPV in 4% of 
223 breast milk samples 3 days postpartum, regardless of the mother’s oral or cervical 
HPV status (Sarkola et al., 2008b). Transmission via infected surfaces or other fomites, 
such as clothes, toys or eating utensils, is also possible. Autoinoculation can occur by 
scratching from one site of the body to another or by bathing (Myhre et al., 2003; Syrjänen 
& Puranen, 2000). HPV is known to multiply locally at the site of entry on the skin or 
mucous membranes; by deduction (logically) there is no viremia and no blood spread, but 
one study showed the presence of HPV in peripheral blood mononuclear cells (PBMCs) 
from HIV-infected pediatric patients and from healthy blood donors (Bodaghi et al., 2005). 
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5. Characteristics of infected benign and malignant head and neck lesions 
and prevalence site by site in head and neck region 
5.1 The recurrent respiratory papillomatosis (RRP) 
As briefly described previously, HNSCCs are characterized by varying rates of incidence 
and mortality around the world, such as higher rates in Southeast Asia and Eastern Europe 
(Kreimer et al., 2005). At present, it is known for certain that HPVs are the etiological agent 
of many benign and malignant tumors arising from epidermal tissues. Nearly thirty years 
ago, Gissmann and colleagues were the first team to detect DNA sequences from HPV types 
6 and 11 in laryngeal papillomas (Gissmann et al., 1983). Laryngeal papillomatosis, also 
known as recurrent respiratory papillomatosis (RRP), is characterized by the recurrent 
growth of exophytic, wart-like lesions called papillomas, along the epithelium of the upper 
respiratory tract, such as the vocal cords, the arytenoids, the subglottis, the trachea and most 
commonly, the larynx (Lacey et al., 2006; Mammas et al., 2009). Although the RRPs are 
benign, their recurrent nature and location in the airways require frequent surgical removal 
and can cause significant morbidity and occasional mortality secondary to airway 
obstruction. Smoking and low-risk or high-risk HPV infections have also been proposed to 
be cofactors in the conversion of laryngeal papillomas into carcinomas (Doyle et al., 1994). 
These lesions were first described in the late 1800s by Sir Morrell Mackenzie, who 
recognized papillomas as distinct lesions of the laryngo-pharynx in children. RRPs are 
mostly caused by the low-risk HPV types 6 and 11, with a more aggressive disease course 
for the latter type. The disease is also categorized into juvenile onset (JORRP) and adult 
onset (AORRP) forms based on age at diagnosis. JORRP can be observed immediately 
during the postnatal period, but it is most commonly diagnosed between two and four 
years. In AORRP, the peak incidence ranges from 20 to 40 years of age, with dysphonia and 
hoarseness, and respiratory obstruction being the most common presenting symptoms in 
children and adults, respectively (Larson & Derkay, 2010). In cases of JORRP, lesions are 
suspected to originate from a perinatal infection of mothers with condylomatous lesions, 
which are an overwhelming risk factor. Thus, the virus is generally transmitted during 
gestation or during birth when the baby passes through the infected birth canal. In a Danish 
study, Silverberg and colleagues demonstrated that maternal condyloma during pregnancy 
increased the risk of JORRP in the child more than 200-fold (Silverberg et al., 2003). 
Moreover, 54% of childhood RRP patients were born to mothers with a history of vulvar 
condylomata at the time of delivery (Hallden & Majmudar, 1986). Among AORRP patients, 
the transmission mechanisms clearly vary. The infection probably results from sexual or 
non-sexual contact with an infected lesion. This evidence has been suggested by a case 
control study that showed AORRP patients were more likely to have more sexual partners 
and to have oral sex than controls (Kashima et al., 1992). Additionally, HPV is also able to 
form latent infections in healthy mucosa, suggesting that AORRP could be due to a 
reactivation of a latent HPV infection acquired during birth (Goon et al., 2007; Larson and 
Derkay, 2010). Thus, the relationship between HPV and laryngeal papillomatosis is well 
established. Indeed, it has been shown that 95% of solitary laryngeal papillomas in adults 
were positive for HPV (Lindeberg & Johansen, 1990). Moreover, Dickens et al. reported 
evidence that 59% of laryngeal papillomas showed the presence of the four most common 
subtypes, including the two low-risk dominant types 6 and 11 (Dickens et al., 1991). In 
general, the prevalence of RRP was estimated at between four to seven cases per million 
person-years, and the incidence is about 2 per 100,000 in adults and 4 per 100,000 in children 
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(Goon et al., 2007). A report in the United States estimated the number of new cases of 
childhood onset RRP was 1500 to 2500 each year (Derkay, 1995). 
5.2 Implication of HPV in other benign lesions of the upper aerodigestive area 
As in RRP, HPV is also involved in the development of different benign lesions occurring 
in the oral cavity, the pharynx, the larynx and the nasopharynx. Numerous studies have 
been conducted on benign tumors arising in the head and neck to evaluate the possible 
role of HPV in head and neck neoplasms. However, its implication in carcinogenesis is 
still controversial because of the different frequencies detected. Kashima et al. examined 
the diagnostic and prognostic relevance of HPV in 26 squamous papillomas and 29 
inverted papillomas. They examined the presence of four HPV types using the PCR 
amplification technique. The proportion of tissue samples showing HPV infection was 
15% and 24% for squamous papillomas and inverted papillomas, respectively, with HPV 
types 6 and 11 being the only two types detected in these lesions (Kashima et al., 1992). 
Four years later, HPV was detected with a prevalence of 81.8% in 22 cases of laryngeal 
squamous papillomas (LP) and 42.5% in 40 cases of nasal inverted papillomas (NIP). HPV 
types 6 and 11 were again implicated, with a slight bias for HPV 6 in LP and HPV 11 in 
NIP, suggesting that HPV may play a role in the development of both lesions, and that 
these viral types may exhibit relative differences in their tissue specificity (Shen et al., 
1996). On the other hand, Hoffmann and colleagues had investigated whether HPV was 
implicated in sinunasal polyposis and found a positive signal in only 1 of the 39 
investigated cases (2.6%) (Hoffmann et al., 2000). In oral and oropharyngeal areas, 
squamous cell papillomas are also benign tumors that occur mainly between 30 and 50 
years of age but still represent about 8% of oral tumors in children (Castro & Filho, 2006). 
Many types of tumors can develop in the oropharynx and oral cavity, such as condiloma 
acuminata, the common wart and focal epithelial hyperplasia (FEH). Condiloma 
acuminata (CA) is often considered a sexually transmitted disease, but the trend is to 
consider that it may also be acquired by auto-inoculation or by maternal transmission 
(Castro & Filho, 2006; Syrjänen, 2003). HPV was detected in CA with a positivity rate 
varying between 75% to 85% for the two most frequent lr HPVs, HPV 6 and 11 (Chang et 
al., 1991; Syrjänen, 2003). Common warts, one of the most common skin lesions, are 
frequently located on the lips, hard palate, gums and tongue dorsum. HPV detection rates 
in oral warts have been shown to vary between 43% and 100% (Padayachee, 1994; 
Praetorius, 1997; Zeuss et al., 1991). Although the near 100% positivity of HPV 6 and 11 is 
well established for the majority of benign tumors, it has been shown that HPV 2 and 
HPV 57 were more prevalent in common oral warts (Padayachee, 1994). Finally, oral focal 
epithelial hyperplasia (FEH), also known as Heck’s disease and characterized by multiple 
nodular elevations, is a third benign oral lesion that may be located in the oral mucosa, 
lower lips and tongue. Like for oral warts, HPV 6 and 11 are not the major types found in 
FEH. Indeed, HPV 13 and 32 have been identified in 75% to 100% of the cases (Praetorius, 
1997). These two types were considered specific to focal epithelial hyperplasia, while HPV 
32 was also found in other oral lesions (de Villiers, 1989). In 2002, Schwenger and 
colleagues showed that 100% of FEH cases tested were positive for HPV 13 and/or 32 
(Schwenger et al., 2002). Moreover, in a recent Brazilian study, of sixteen benign tumors 
found among 86 examined oral lesions, 100% were positive for HPV (Lira et al., 2009). To 
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confirm the great prevalence of HPV in benign laryngeal lesions, Arndt et al. assessed the 
presence of HPV genomes 6, 11, 16, 18, 31, 33 and 35 in 17 juvenile laryngeal papillomas 
(JLP), 27 adult laryngeal papillomas (ALP), 15 oral papillomas (OP) and 11 laryngeal 
leukoplakias (LL). The results showed 100% positivity for HPV 6 and 11 in JLP and ALP, 
87% in OP and 63% in LL, whereas hr HPV 16, 18 and 33 were found in 22% of ALP, 20% 
of OP and 36% of LL, suggesting that the role of HPV in malignant transformation is less 
clear than in benign tumors (Arndt et al., 1997). In 2005, a combination of PCR and nested 
PCR was applied to improve the detection level of infected samples. Among 27 biopsies 
from different head and neck regions, such as the larynx, nasal cavities and sinuses, 
pharynx and oral cavity, 16 showed a positive result in either PCR or nested PCR or both, 
suggesting that this PCR system is a reliable tool for the detection of HPV DNA in benign 
lesions of the upper aerodigestive tract (Fisher et al., 2005). Conversely, in a retrospective 
study, 36 head and neck papillomata were tested for HPV 6, 11, 16 and 18 using PCR, and 
the results were not consistent with a role for HPV infection in the etiology of head and 
neck papillomata in adult patients. In fact, only 20% of benign tumors were positive for an 
HPV type (Campos-Bañales et al., 1995). Finally, in 2011, we assessed the presence of HPV 
DNA in a series of 39 laryngeal benign lesions (LBLs) from 20 cases of vocal nodules, 13 
cases of chronic laryngitis and 6 cases of papillomas. The analysis was performed by PCR 
using the GP5+/GP6+ primers that amplify a conserved sequence located within the L1 
region of the HPV genome. Next, all DNA extracts were tested for the presence of 18 
different HPV genotypes using TaqMan-based real-time quantitative PCR. Four out of 39 
specimens had insufficient tissue quantities for DNA extraction after pathological 
evaluation and were, therefore, excluded from further analyses. Note that PCR was also 
performed using ǃ-globin primers to demonstrate the presence of amplifiable DNA in the 
tissue extracts. All 35 LBLs gave positive signals for ǃ-globin. Among these 35 cases, we 
identified 27 lesions (77%) that were positive for HPV 16. In the hr HPV-negative 
subgroup (n=8), two specimens tested positive for HPV using the GP5+/GP6+ consensus 
primers and were considered infected with lr HPV types (Fig. 1). Only six benign lesions 
were negative in both GP5+/GP6+ and type-specific HPV PCR analyses (17%). Among 
the 27 hr HPV-positive lesions, 12 were both positive for GP5+/GP6+ and type-specific 
HPV (hr HPV+ group), whereas 15 were negative for GP5+/GP6+ and positive for type-
specific HPV, which corresponds to the integrated HPV-positive group (int. hr HPV+) 
(Fig. 1) (Duray et al., 2011a).  
This discrepancy observed in varying rates of incidence is mainly attributed to a variation in 
the sensitivity of the methods employed and in the epidemiological factors related to the 
group of patients examined. Indeed, the different methods have been classified in three 
categories according to the detection threshold of viral DNA copy number in the cell: 
techniques having a low sensitivity, such as immunohistochemistry and in situ 
hybridization; techniques with moderate sensitivity, such as Southern blot, dot blot and 
reverse dot blot hybridizations; and techniques displaying high sensitivity, such as the 
polymerase chain reaction, which can detect the virus in less than one copy per cell (Castro 
& Filho, 2005). Nevertheless, each method is limited by its sensitivity, its specificity, its 
practice and its cost, among other limiting factors. In conclusion, it is important to assess the 
efficacy of the different HPV detection techniques in order to establish HPV etiology in oral 
lesions.  
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
242 
 
Fig. 1. HPV PCR results from 39 OSCC cases. Four samples could not be analyzed due to 
insufficient material, and ǃ-globin could be amplified in all samples. Therefore, 35 cases in 
total were analyzed by type-specific real-time PCR and GP5+/GP6+ consensus PCR. Among 
these patients, 77% tested positive for infection with one or several types of hr HPV, 6% 
tested positive for lr HPV and 17% were HPV-negative. 
5.3 Implication of HPV in malignant tumors of the upper aerodisgestive area 
5.3.1 Incidence in hypopharyngeal tumors 
HNSCC represents the sixth most common malignancy with an annual incidence of more 
than 600,000 cases worldwide and is responsible for approximately 350,000 deaths each year 
(Parkin et al., 2005). These cancers mainly comprise the hypopharyngeal, laryngeal, 
oropharyngeal and oral cancers. Depending on the anatomical location of the primary 
tumor, HNSCCs show an HPV prevalence of between 20% and 30% for hypo-, laryngeal and 
oral carcinomas and up to over 50% for tonsillar squamous cell carcinomas, especially 
Waldeyer’s tonsillar ring (Deng et al., 2011). Furthermore, there is a persistent controversy 
on the role of HPV infection in HNSCC progression and on the influence of these infections 
on the final clinical outcome. Hypopharyngeal carcinoma is one of the less documented 
head and neck cancers in the literature. Indeed, few studies are exclusively devoted to 
hypopharyngeal cancers. Thus, the few cases available arise from certain studies that 
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sometimes include hypopharyngeal cases in their cohort. Based on the literature, we 
observed a prevalence ranging from 0% to 82% (Ernoux et al., 2011; Hafkamp et al., 2003; 
Ringström et al., 2002). In fact, some authors failed to show prevalence higher than 10% 
(Gillison et al., 2000; Hafkamp et al., 2003; Ribeiro et al., 2011; Ringström et al., 2002; 
Stremlau et al., 1987), whereas others found prevalence greater than 50% (Arndt et al., 1992; 
Ernoux et al., 2011; Kleist et al., 2000; Koskinen et al., 2003; Tyan et al., 1993). Recently, we 
examined the presence of HPV DNA in a series of 75 patients with stage IV hypopharyngeal 
SCC (Ernoux et al., 2011). The same methods used previously to detect the virus in our 
paraffin-embedded samples (PCR using GP5+/GP6+ primers and subsequent TaqMan-
based real-time quantitative PCR targeting type-specific sequences of 18 HPV types) were 
employed in the study. Of the 75 specimens, 8 had insufficient tissue for DNA extraction or 
quantitative PCR and were, therefore, excluded from further analysis (Fig. 2). Of the 
remaining 67 cases, another 6 from which were ǃ-globin PCR-negative were also excluded 
from further analysis. Ultimately, 61 ǃ-globin PCR-positive specimens were typed by 
quantitative real-time PCR using primers for 18 different HPV types (Fig. 2). 
 
Fig. 2. HPV PCR results from 75 OSCC cases. Eight samples could not be analyzed due to 
insufficient material, and ǃ-globin could not be amplified in six additional samples. 
Therefore, 61 cases in total were analyzed by type-specific real-time PCR and GP5+/GP6+ 
consensus PCR. Among these patients, 82% tested positive for infection with one or several 
types of hr HPV, 7% tested positive for lr HPV and 11% were HPV-negative. 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
244 
From this homogeneous group of 61 HSCC tumor specimens, we identified 50 samples 
(82%) that tested positive for the following hr HPV types: HPV 16 (37 cases), 18 (4 cases), 33 
(11 cases), 39 (1 case), 51 (5 cases), 53 (1 case), 58 (2 cases), 59 (1 case) and 66 (4 cases), four 
(7%) were positive for lr HPV types and seven (11%) were negative. Twelve samples were 
infected with multiple types of hr HPV. Among the 50 hr HPV-positive tumors, 38 were 
both GP5+/GP6+ positive and type-specific HPV-positive (hr HPV+ group). However, 12 
tumors were GP5+/GP6+ negative and type-specific HPV-positive, corresponding to an 
integrated HPV+ group (int. hr HPV+) (Fig. 2). 
This disagreement over HPV prevalence may be explained by the sensitivity of the methods 
used and the number of cases enrolled. Indeed, the use of different detection methods and 
HPV-specific probes, as well as varying numbers of tissue samples from different locations, 
has caused confusion over the frequency of HPV-positive lesions. Despite using the most 
sensitive method (PCR), we still observed a large variation in HPV detection rates, which 
can be explained by the relationship between results and sample sizes. In fact, the Kleist et 
al. study observed an 80% positivity among 5 samples, while Ribeiro et al. only detected 
HPV in 3.8% of cases among 78 tumors (Kleist et al., 2000; Ribeiro et al., 2011). 
Concerning prognosis, statistical analysis did not reveal a significant correlation between hr 
HPV positivity and the proportion of disease-free patients. However, 32% (16/50 cases) of 
patients with hr HPV-positive tumors experienced relapse, compared with 8% of patients 
with HPV or lr HPV-positive tumors. The five-year disease-free survival was 88% in HPV 
negative and lr HPV-positive tumors versus 58% in hr HPV-positive tumors (Fig. 3). 
 
Fig. 3. Disease-free survival curves for high-risk HPV+ (hr HPV+) versus HPV negative and 
low-risk HPV+ (lr HPV+) patients. The p-value is not significant (NS) 
As mentioned above, few publications have focused on HPV positivity in hypopharyngeal 
cancers. Evidently, our results are in accordance with a previous study by Morgan et al, who 
described for the first time that 75% of the 16 pharyngolaryngeal carcinomas in their series 
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were HPV-positive (Morgan et al., 1991). Another study found a lower HPV positivity rate 
(46%) in tumors from 78 previously untreated patients with laryngeal and hypopharyngeal 
carcinomas (Clayman et al., 1994). The authors concluded that HPV-positive tumors 
represented a biologically distinct subset of tumors that had a worse prognosis than HPV 
negative tumors (Clayman et al., 1994). In contrast to our results, Paz et al. did not identify 
any HPV-positive tumors in a small series of seven hypopharyngeal carcinoma patients (Paz 
et al., 1997). Indeed, conclusions are difficult to draw, given the lack of interest in the 
prognostic outcomes of these cancers, but it would seem that HPV-associated 
hypopharyngeal carcinomas are characterized by a poorer prognosis, or a tendency towards 
having a poorer prognosis, than HPV-negative hypopharyngeal carcinomas (Clayman et al., 
1994; Ernoux et al., 2011). Thus, HPV infection may be closely associated with the 
development of some hypopharyngeal carcinomas.  
5.3.2 Incidence in laryngeal tumors 
Laryngeal squamous cell carcinoma (LSCC) is the most frequent malignant tumor in the 
upper aerodigestive tract and is found predominantly in males. Although the relationship of 
HPV with SCC in the larynx is not well established, oncogenic HPVs have been proposed to 
be potential pathogenic factors. Studies focusing on HPV infections in LSCCs have reported 
wide variations in infection frequency that range from 0% to 85% (Almadori et al., 1996; 
Boscolo-Rizzo et al., 2009; Gallo et al., 2009; García-Milián et al., 1998; Koskinen et al., 2007; 
Lindeberg & Krogdahl, 1999; Rees et al., 2004). The prevalence varied widely with 
individual investigations. More than ten years ago, Brandwein et al. and Lie et al. reported 
that only 8% of LSCCs in the USA and Norway contained HPV DNA (Brandwein et al., 
1993; Lie et al., 1996). Other authors also showed prevalence lower than 10%. In 1999, 
Lindeberg and Krogdahl demonstrated HPV infection in only one of 30 laryngeal 
carcinomas (Lindeberg & Krogdahl, 1999). More recently, in a cohort of 69 LSCC patients, 3 
(4.4%) had HPV-positive samples, whereas other investigators did not find any HPV-
positive samples among 68 LSCCs (Gallo et al., 2009; Koskinen et al., 2007). These findings 
support the view that the role of HPV in LSCC is less important in the larynx and also 
suggest the existence of other factors that play a more important role than viral infection in 
the carcinogenesis of these lesions. However, when we examine the few studies considering 
more than 80 patients with PCR-based analytical techniques, we observe higher percentages 
than previously demonstrated. Reports that include small sample sizes are subject to a 
potential selection bias. Indeed, the prevalence detected by Morshed et al. rose to 35.5%, but 
they did not find any significantly improved overall or disease-specific survival compared 
to patients with HPV-negative tumors (Morshed et al., 2008). In the same manner, high-risk 
HPV was found in 41 out of 110 LSCCs (37.3%) in a Brazilian study (de Oliveira et al., 2006). 
Larger samples being better, Syrjänen analyzed 116 LSCCs using in situ hybridization to 
demonstrate the presence of HPV DNA from types 6, 11, 16 and 30 in paraffin-embedded 
biopsies. A total of 15 of 116 (12.9%) tumors were shown to contain HPV DNA of at least 
one type (Syrjänen et al., 1987). This low prevalence can be explained by the use of a 
technique with lower sensitivity than PCR, which has the greatest sensitivity. Additionally, 
our study focused on HPV detection in a sample of 67 laryngeal SCCs revealed a 75% 
prevalence of high-risk HPV, as shown in Figure 4 (Duray et al., 2011a). To prevent false 
positives, precautions were taken to prevent tissue contamination. Our results may be 
explained by the fact that we used a sensitive (10-100 copies per PCR reaction) and type-
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specific real-time quantitative PCR analysis with a short amplification product (60-80 bp) 
that is more sensitive to the presence of degraded DNA, which is typically found in 
paraffin-embedded specimens. 
 
Fig. 4. HPV PCR results from 67 LSCC cases. Six samples could not be analyzed due to 
insufficient material, and ǃ-globin could not be amplified in two additional samples. 
Therefore, 59 cases in total were analyzed by type-specific real-time PCR and GP5+/GP6+ 
consensus PCR. Among these patients, 75% tested positive for infection with one or several 
types of hr HPV, 5% tested positive for lr HPV and 20% were HPV-negative. 
In this study, we also considered the prognostic value of the presence of hr HPV DNA in 
laryngeal carcinomas. We observed that positive hr HPV status did not correlate with the 
proportion of disease-free patients (Fig. 5). The five-year disease-free survival was 87% in 
HPV-negative or lr HPV-positive early-stage tumors versus 76% in hr HPV-positive early-
stage tumors (Fig. 5A). The five-year disease-free survival was 60% in HPV-negative or lr 
HPV-positive late-stage tumors versus 58% in hr HPV-positive high-stage tumors (Fig. 5B). 
After grouping the early and late stages, the five-year disease-free survival was 77% in HPV-
negative or lr HPV-positive laryngeal tumors versus 67% in hr HPV-positive laryngeal 
tumors (Fig. 5C). Similarly, Boscolo-Rizzo et al. found no significant differences in overall 
survival and disease-free survival between patients with HPV-positive tumors and patients 
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with HPV-negative tumors (Boscolo-Rizzo et al., 2008). Although there is strong support in 
the literature for the association between HPV-positive tumors and better prognosis, 
especially in oropharyngeal carcinomas, other studies did not find an improved prognosis 
for HPV-associated tumors (Clayman et al., 1994; Dahlstrand et al., 2008; Ernoux et al., 2011).  
 
Fig. 5. Disease-free survival curves for high-risk HPV+ (hr HPV+) versus HPV- and low-risk 
HPV+ (lr HPV+) patients with low- (A) and high-stage (B) laryngeal carcinoma. (C) Disease-
free survival curves for all stages together. The p-values were not significant (NS). 
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Although preliminary results may suggest biological oncogenic activity, the role of HPV 
infection in LSCCs has not been clearly established. Thus, in view of conflicting results, 
reports of the frequency of HPV infection in laryngeal carcinomas should be interpreted 
with caution, and despite low prevalence, there is no doubt that HPV is present in a subset 
of laryngeal carcinomas. Thus, we should not exclude the possibility of a causal relationship 
between HPV and some laryngeal tumors. Prospective studies with large numbers of 
patients and controls are required to confirm this hypothesis. 
5.3.3 Incidence in oral tumors 
Questions remain as to whether HPV is causally associated with cancer development at 
other sites in the upper aerodigestive tract. Its role continues to be a topic of debate, as a link 
with HNSCC was suggested more than 20 years ago (Syrjänen et al., 1983). Based on light 
microscopy examination, they observed koilocytosis, which is the presence of cytopathic 
HPV-induced alterations, in 35% of oral squamous cell carcinoma (OSCC) biopsies that were 
identical to those found in precancerous lesions and in uterine cervical carcinoma. Several 
meta-analyses have been dedicated to the relationship between HPV and OSCC (Kreimer et 
al., 2005; Miller & Johnstone, 2001; Syrjänen et al., 2011; Termine et al., 2008). The prevalence 
reported by these studies is quite different (23.5%, 33.7%, 38.1%, and 46.5%). This variability 
could be explained by different manner: Termine et al. included studies examining more 
than 40 specimens, and they calculated their prevalence exclusively on the basis of paraffin 
embedded (PE) specimens. On the other hand, Miller and Johnstone, similar to Kreimer et 
al., did not report HPV prevalence in PE and fresh frozen (FF) specimens separately. Miller 
and Johnstone were the first to publish a meta-analysis on HPV prevalence in normal and 
cancerous oral lesions. Pooled data from non-controlled studies published between 1982 and 
1997 showed that HPV was 4.7 times more likely to be present in oral carcinomas when 
compared with normal mucosa (Miller & Johnstone, 2001). More recently, the interesting 
systematic review by Syrjänen et al. observed a pooled HPV detection rate of 33.7% in the 
OSCC group compared with 12% in the control group. The authors concluded that HPV 
infection significantly increases the risk for OSCC. It is important to note that the association 
of HPV with OSCC was significant only when HPV was detected in biopsy samples and that 
this significant association was completely lost when only exfoliated cells were used to 
analyze HPV in both cases and controls. Herrero et al. also showed that HPV DNA in 
exfoliated cells was not associated with HPV DNA detection in OSCC samples (Herrero et 
al., 2003). Thus, to obtain the most accurate results for the relationship between HPV and 
OSCC, future studies should only select biopsied tissues for HPV testing. In addition to the 
previously mentioned reviews, studies examining HPV infection in OSCC reported a wide 
range of detection rates from 0 to 61% (Herrero et al., 2003; Koskinen et al., 2003; Mishra et 
al., 2006; Ribeiro et al., 2011; Smith et al., 2004a). Varying sampling techniques together with 
widely divergent PCR methods across the studies explain most of this variability. Other 
criteria have also been considered: i) the specificity and size of PCR primers (e.g., 
GP5+/GP6+, MY09/11,…), ii) the geographical demographics, iii) the number of enrolled 
cases and iv) the prevalence of smoking and alcohol consumption in the studied population. 
A similar prevalence was detected by Zhao et al, who found 40.4% positivity (21 of 52 
samples) with HPV 16 accounting for 63.5% and HPV 18 for 30.8%. Moreover, HPV had an 
independent prognostic effect on the overall survival of OSCC after adjusting for other 
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factors, such as histological grade, TNM stage and tobacco use. Another characteristic was 
the significant correlation with improved survival in OSCC patients (Zhao et al., 2009). In 
2001, Schwartz et al. also demonstrated that HPV16 presence was independently related to a 
favorable prognosis in a population of 254 OSCC patients (Schwartz et al., 2001). Gillison’s 
well-controlled study found that oral cancers containing oncogenic HPV types had 74% less 
risk of disease-specific mortality (Gillison et al., 2000). On the other hand, many studies have 
also demonstrated that the prevalence of high-risk HPV types was low in OSCCs. Indeed, 
recently, only 2% of the PE tissues analyzed tested positive in Lopes study (Lopes et al., 
2011). Almost the same observation was made by several studies using qPCR techniques 
(Boy et al., 2006; Ha et al., 2002; Koskinen et al., 2003). Furthermore, a meta-analysis 
suggested that the association between HPV and cancer was strongest for the tonsils, 
intermediate for the oropharynx and weakest for the mouth and larynx (Hobbs et al., 2006). 
In contrast, a Hungarian study demonstrated that 31 of 65 (48%) oral cancer cases had 
evidence of HPV using qPCR methods, reflecting the impact of geographical variation 
(Szarka et al., 2009). In fact, geographical origin is a well-known variability factor regarding 
HPV prevalence, with Asia having the highest worldwide frequency and Africa having the 
lowest (Termine et al., 2008). A hypothesis was suggested that OSCC HPV prevalence could 
be biased and overestimated because of a non-precise assignment of the anatomical site 
resulting in a “contamination” of the OSCC cohort with oropharyngeal cancers (Lopes et al., 
2011). Once again, the detection methods remain the argument of choice to compare the 
different results obtained. In fact, two teams recently proposed two methods for HPV 
detection: in situ PCR and in situ PCR ISH. These methods combine the sensitivity of 
solution PCR with the subcellular localization provided by traditional ISH (Koyama et al., 
2007; Uobe et al., 2001). Nevertheless, there are currently insufficient data in the literature to 
support the adequacy of these techniques. Finally, in our study, the prevalence of HPV 
infection reached 70%, with 44% being hr HPV-positive and 26% being lr HPV-positive (Fig. 
6) (Duray & Descamps et al., in revision). The high incidence of HPV in our samples may 
also be explained by the fact that a very sensitive PCR (GP5+/GP6+ primers: 10–100 copies 
per reaction) was combined with a type-specific real-time quantitative PCR analysis and a 
short amplification product (60–80 bp). To a similar end, Termine et al. demonstrated that 
PCR-based studies resulted in higher prevalence rates compared with studies using in situ 
hybridization (Termine et al., 2008). Our results confirmed this finding because almost 65% 
of HPV+ specimens where also positive using ISH, whereas the ISH/PCR correspondence 
was excellent for the negative specimens.  
Moreover, high-risk HPV positivity was associated with shorter disease-free survival in 
our cohort of 147 OSCC patients. The five-year disease-free survival was 76% for patients 
with HPV-negative tumors versus 40% for patients with HPV-positive tumors (p=0.007) 
(Fig. 7A). Furthermore, the five-year disease-free survival was 48% for patients with lr 
HPV-positive tumors versus 37% for patients with hr HPV-positive tumors (p=0.015) (Fig. 
7B). These data suggest that HPV infection was significantly associated with a worse 
prognosis. Moreover, Cox multivariate analyses combining the HPV status with clinical 
variables (TNM staging and node status) demonstrated that only HPV status had an 
independent impact on patient prognosis (p=0.01; hazard ratio=2.81). An analysis of viral 
loads in infected patients did not show any statistically significant relationship between 
TNM staging and risk of recurrence.  
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Fig. 6. HPV PCR results from 162 OSCC cases. Six samples could not be analyzed due to 
insufficient material, and ǃ-globin could not be amplified in nine additional samples. 
Therefore, 147 cases in total were analyzed by type-specific real-time PCR and GP5+/GP6+ 
consensus PCR. Among these patients, 44% tested positive for infection with one or several 
types of hr HPV, 26% tested positive for lr HPV and 30% were HPV-negative. 
Although a majority of studies demonstrated an improved outcome for OSCC patients, the 
meta-analysis by Ragin and Taioli examining the relationship between HPV and overall 
survival did not show any survival differences between HPV-positive and HPV-negative 
patients with cancers at non-oropharyngeal sites (Ragin & Taioli, 2007). The same 
observation was made by Gillison et al., suggesting that these tumors may have an etiology 
distinct from that of tumors at non-oropharyngeal sites (Gillison et al., 2008). The poor 
prognosis reported in the hr HPV-positive population in this study has been demonstrated 
in other studies. Indeed, two Swedish studies demonstrated that oral HPV infection was 
associated with a dramatically increased risk of developing OSCC (Hansson et al., 2005; 
Rosenquist et al., 2007). Additionally, in 1994, Clayman et al. also showed that HPV 
detection was significantly correlated with decreased survival (Clayman et al., 1994). Other 
studies have failed to demonstrate an association between HPV positivity and prognosis 
(Ernoux et al., 2011; Morshed, 2010). We hypothesize that immunosuppression may favor 
HPV infection (Duray et al., 2010). In 2004, Kreimer reported that tonsillar HPV infection 
was strongly associated with HIV co-infection and immunosuppression (Kreimer et al., 
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2004). Recently, herpes simplex virus-2 (HSV2) infection was demonstrated to increase the 
risk of HPV infection (Moscicki et al., 2001). Furthermore, a study performed by Tung et al. 
reported the presence of HPV 16 or 18 and Epstein Barr virus (EBV) in 80% of 
nasopharyngeal carcinoma samples (Tung et al., 1999). These co-infections may play an 
important role in the initiation of neoplastic transformation in human oral epithelial cells. In 
conclusion, the effect of HPV on oral cancer remains contentious. Thus, to formally confirm 
the role of HPV as an etiological agent in OSCC, sample processing and PCR analysis 
protocols should be standardized to allow a more precise comparison of the results. 
Furthermore, future studies should report separately the type-specific prevalence rates. This 
information would be very useful in order to evaluate the long-term effects of the recent 
HPV vaccines.  
 
Fig. 7. The HPV+ subgroup (and specifically the hr HPV + subgroup) is associated with a 
worse prognosis (p = 0.007 and p = 0.015). Standard survival time analyses were performed 
using Kaplan-Meier curves, the Gehan-Wilcoxon text and the Log-rank test. 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
252 
5.3.4 Incidence in oropharyngeal tumors 
During the past several years, an increased incidence of oropharyngeal squamous cell 
carcinoma (OSCC), the head and neck cancer in which HPV is commonly found, was 
observed. In 2007, Sturgis and Cinciripini proposed a possible emerging epidemic of HPV-
associated cancers (Sturgis & Cinciripini, 2007). Indeed, accumulating molecular and 
epidemiological data now show that hr HPV types are responsible for a subset of OSCCs 
(D’Souza et al., 2007; Lindquist et al., 2007). Therefore, the International Agency for Research 
on Cancer (IARC) recognized HPV as a risk factor for oropharyngeal cancer. In the United 
States, the prevalence of HPV in OSCC has evolved over the last 30 years. Based on data 
from Colorado, the percentage rose from 33% during the 1980s to 70% in the 1990s and 82% 
during 2000 to 2004 (Ernster et al., 2007). During the 2000s, different prevalence rates were 
reported, ranging from 63% to 92% among oropharynx, tongue and tonsil cases (Brown et 
al., 2011). Tonsillar cancer is the most common oropharyngeal cancer, followed by cancer of 
the base of the tongue, and these two cancers accounts for 90% of all OSCCs (Dahlstrand & 
Dalianis, 2005). In Stockholm, as in the USA, HPV prevalence among tonsil cases increased 
over the years from 23% in 1970 up to 83% in 2003 to 2007 (Nasman et al., 2009). In contrast, 
in Beijing, the prevalence of tonsillar cancers is particularly low, with rates of 0.1% in men 
and 0.0 in women. Interestingly, in places with a marked Western influence, such as Hong-
Kong and Taiwan, rates of tonsillar cancer were 6 to 12 times higher than in Beijing 
(Marklund & Hammarstedt, 2011). Large variations in incidence rates are also observed. In 
Europe, the highest rates were seen in France, particularly in Somme region, where the rates 
were as high as 6.4% for men (Parkin et al., 2002). Similar to HNSCC, the prognosis for 
OSCC is generally low in the more advanced stages with an overall five-year survival rate of 
approximately 25% (Licitra et al., 2002). Nevertheless, in HPV infected OSCC, a major 
feature noted in almost all studies is that HPV is a favorable prognostic factor for clinical 
outcome independently of tumor stage, age, gender and grade of differentiation. In fact, 
patients with HPV DNA-positive tumors appear to have a significant prognostic advantage 
compared with patients having HPV-negative tumors (Ang et al., 2010). However, previous 
studies have suggested that the presence of HPV DNA in tumor tissue was not a sufficient 
factor to indicate an involvement of the viral genes in tonsillar carcinomas. Good indicators 
reflecting an active involvement of HPV are the levels of viral E6-E7 mRNA (Cuschieri et al., 
2008). Thus, E6 and E7 expression are regularly assessed with success, suggesting an active 
involvement of HPV in the etiology of tumors (Lindquist et al., 2007). Recently, an 
interesting study provided strong evidence that HPV status was an independent prognostic 
factor for overall survival among patients with OSCC, which may confirm that HPV-
positive and HPV-negative OSCC constitute two distinct clinical entities with different 
causes, risk factor profiles and survival outcomes. To validate this hypothesis, future clinical 
trials should be designed specifically for patients with HPV-positive or HPV-negative OSCC 
(Ang et al., 2010). Concerning this improved survival, Lindquist et al. observed a difference 
between HPV patients who smoked and did not smoke. In fact, patients with HPV-positive 
tonsillar cancer who had never smoked had a better prognosis than those who were 
smokers, which is in accordance with the studies of Ang and Rotnaglova (Ang et al., 2010; 
Lindquist et al., 2007; Rotnaglova et al., 2010). These observations may be explained by an 
immune response induced by HPV but abrogated by smoking. A different option, also 
suggested by Ang et al, is that smoking and HPV are associated with different categories of 
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tumors and that smoking induces additional genetic alterations in these tumors (Ramqvist & 
Dalianis, 2010, Ang et al., 2010). Some investigators have suggested that the better clinical 
outcome can be attributed either to higher radiosensitivity of HPV-positive tumors or to 
active antiviral cellular immune responses in infected patients (Dahlstrand & Dalianis, 
2005). Treatment of patients with advanced disease often includes both oncological and 
surgical treatment, as both carry acute side effects, such as difficulties in swallowing or 
talking, dry mouth and jawbone necrosis. Oncological treatment has fortunately evolved 
towards the development of altered fractionation radiotherapy, integration of chemotherapy 
with radiotherapy and the introduction of targeted biological therapy. The combined 
modality treatment and the intensified fractionation have improved the outcome for head 
and neck cancer patients in general (Bourhis et al., 2006; Pignon et al., 2009). As a result of 
this intensified therapy, patients have substantial chronic side effects. It is therefore 
important to differentiate patients who do and do not need intensified treatment to increase 
patient survival times and quality of life. The improved response to oncological treatment 
for OSCC HPV-positive patients may also be explained by the presence of an intact p53-
mediated apoptotic response in HPV-positive tumors and by immunological factors related 
to HPV infection (Spanos et al., 2009). In conclusion, HPV-positive OSCC is recognized as a 
distinct subset of head and neck squamous cell carcinomas having a favorable outcome. 
Patients with HPV-positive tonsillar carcinomas may also benefit from a less aggressive 
treatment, but this conclusion will need to be validated by further studies in order not to 
compromise existing, excellent treatment outcomes in patients with HPV-dependent 
tumors.  
6. Impact of HPV on the immune system of head and neck cancers 
6.1 The escape of HPV in the immune system 
The contradiction between the studies examining the correlation between HPV infection and 
prognosis may result from differences in immune status among HNSCC patients. In fact, a 
persistent HPV infection that can lead to the development of cancer requires immune 
tolerance. Therefore, HPV has developed several mechanisms to avoid detection by the host 
immune defense system. In the case of infection by a virus, it is important to distinguish 
between the mechanisms used by tumor cells to evade immune attack and those used by 
HPV. The infectious cycle of HPV is itself an immune evasion mechanism because viral gene 
expression and viral protein synthesis are confined to keratinocytes, which are programmed 
to die; thus, HPV replication does not cause cell death and does not present a danger signal 
to the immune system (Stanley, 2006, 2009). Without cell lysis, there is little or no release of 
the proinflammatory cytokines important for the activation and migration of dendritic cells 
(Stanley, 2006, 2009). Even if there is no cell death, keratinocytes should be activated to 
induce type I interferon responses, which have anti-viral, anti-proliferative, anti-angiogenic 
and immune-stimulatory properties. Several data suggest that E6 and E7 oncogenes have 
evolved mechanisms to interact with components of the interferon pathway and to 
downregulate the effects of type I IFN (Stanley, 2009). For instance, the virus maintains a 
low level of viremia, there is no blood-borne phase and only minimal amounts of replicating 
virus are exposed to the immune system. As a result of these facts, the virus is practically 
invisible to the host (Kanodia et al., 2007; Stanley, 2009). HPV is able to dysregulate the 
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antigen processing machinery (APM) by downregulating peptide-MHC complexes, which 
are essential for recognition of infected cells by T cells. In particular, the E7 oncoprotein of 
HPV-16 and -18 repress the promoter for MHC class I heavy chain expression, and HPV-18 
E7 is also able to repress the promoter that regulates expression of TAP1 (transporter 
associated with antigen protein 1) and LMP2 genes (Georgopoulos et al., 2000). HPV-16 E5 
induces alkalinization of the Golgi complex, leading to disruption of trafficking, including 
transport of the MHC class I complex (Ashrafi et al., 2005). In HPV-positive benign 
laryngeal lesions, there is a decrease of MHC class I and TAP-1 expression, and the low 
expression of TAP-1 was associated with rapid recurrence of the disease (Bonagura et al., 
1994; Vambutas et al., 2000). Another way in which HPV may suppress immune responses 
is via the modulation of chemokine (suppression of MCP-1 expression, downregulation of 
IL-8 expression) and pro-inflammatory cytokine (downregulation of IL-18 expression) 
expression and via skewing the cytokine profile in favor of a Th2 response (IL-4, -5, -6, -10, -
13) instead of a Th1 cytokine expression (IL-2, IFN-Ǆ) (Kanodia et al., 2007). Moreover, the 
E6 and E7 oncoproteins downregulate toll-like receptor 9 (TLR9), which induces 
proinflammatory genes essential for induction of immune responses (Hasan et al., 2007). 
The failure of the immune system to recognize HPV may also be explained by the fact that 
HPV16 E7 protein has widespread similarity to several human proteins, such as xeroderma 
pigmentosum group G complementing protein (XPGC) and the retinoblastoma binding 
protein 1 (RBP-1); thus, the immune system does not recognize them as foreign molecules 
but as self molecules (O’Donovan et al., 1993; Scherly et al., 1993).  
6.2 Defects in the immune system of HNSCC patients 
Patients suffering from head and neck cancers exhibit deficits in the humoral and cellular 
immune systems, which have been shown to be correlated with a worse prognosis. The 
strategies employed by head and neck cancers to escape the immune system are varied: they 
can directly inhibit the immune response by producing soluble mediators or they can target 
the APM via downregulation of HLA class I and/or other components of the APM (Duray 
et al., 2010). In the first steps of carcinogenesis, there is an increase of Langerhans cells, 
whereas in invasive carcinomas, a decrease was observed (Fig.8). The accumulation of 
macrophages in the peritumoral area seems to play a protumoral role by secreting VEGF 
and stimulating angiogenesis (Duray et al., 2010) (Fig.8). Antitumor responses of HNSCC 
patients are compromised in the presence of functional defects or apoptosis of T-cells, both 
circulating and tumor-infiltrating. Functional assays with tumor-infiltrating lymphocytes 
TILs isolated from the tumor bed have identified a number of defects, such as (i) absent or 
low expression of the CD3 zeta chain (CD3ζ), which is the key signaling molecule in the T-
cell receptor pathway (Whiteside, 2005), (ii) decreased proliferation in response to mitogens 
or IL-2 (Whiteside, 2005), (iii) the inability to kill tumor cell targets (Hathaway et al., 2005; 
Hoffmann et al., 2004), (iv) an imbalance in the cytokine profile, with a striking absence of 
IL-2 and/or IFN-Ǆ production (Reichert et al., 1998a), and (v) evidence of pronounced 
apoptotic features in a considerable proportion of TILs (Whiteside, 2005; Young et al., 1996). 
Several studies demonstrated the involvement of the Fas/FasL signaling pathway, the 
mitochondrial pathway, TRAIL, and TNF-ǂ in the apoptosis of T cells in HNSCC patients 
(Duray et al., 2010). Furthermore, changes in the expression of the ζ chain of TILs are 
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biologically significant because the absence or low expression of this chain in TILs in 
patients with stage III or IV HNSCC predicts a poor survival compared with patients 
expressing a normal ζ chain (Reichert et al., 1998b; Whiteside, 1999). Another study showed 
that patients with more aggressive tumors or with a recurrence within the preceding two 
years expressed the lowest levels of the ζ chain (Kuss et al., 1999). Various studies showed 
an increased abundance of T regulatory cells Tregs in TILs and peripheral blood, and their 
immunosuppressive action could be another mechanism employed by the tumor cells to 
escape antitumor immunity. Lau et al. demonstrated an increase of Tregs in patients with 
nasopharyngeal carcinoma, and their suppression of the proliferation of CD4-
positive/CD25-negative T cells could explain the decreased antitumor immunity of T cells 
(Lau et al., 2007) (Fig.8).  
6.3 Effects of HPV on the immune system of patients with benign or malignant lesions 
of the upper aerodisgestive area 
Considering the high HPV prevalence in the population, it remains unclear why a very 
small fraction of HPV-exposed individuals develop RRP. To better understand this result, 
Bonagura and colleagues studied the differences between RRP patients infected with HPV-6 
or -11 and healthy individuals who were also infected with HPV but never developed RRP. 
They provided evidence that there are several immune alterations in patients with RRP, 
such as (i) an adaptative immune response induces a Th2-like/T-regulatory phenotype. In 
fact, patients with RRP displayed elevated levels of Th2-like chemokines (CCL17, CCL18, 
CCL22) and cytokines (IL-4, IL-10), whereas levels of TH1-like chemokines (CCL19, CCL21) 
and cytokines (IL-12, IL-18, IFN-Ǆ) were downregulated. In papillomas, there is an 
enrichment of Tregs, which suppress Th1-like responses to HPV. (ii) Interestingly, the 
expression of IL-4 by CD4-positive T cells was increased in papillomas, whereas the 
expression of IFN-Ǆ was reduced. An expression of IL-10 by CD4-positive T cells was also 
observed in the blood (PBMCs) of patients with RRP. These findings suggest that CD4-
positive T cells express TH2-like cytokines and reduce Th1-like T-cell function. (iii) A 
decrease of CD4-positive and CD8-positive T cell Vǃ repertoires. Moreover, they showed 
that HPV-11 E6 can suppress T-cell alloreactivity and that natural killer cells are 
dysfunctional in RRP. Furthermore, they also proposed an inhibitory cycle of immunocytes 
that support the development of RRP. In response to HPV proteins, memory Th2-like T cells 
express IL-4 and IL-10, and T-regulatory cells express IL-10 and TGF-ǃ, inducing resting 
macrophages to become alternatively activated macrophages. These macrophages express 
TH2-like chemokines (CCL17, CCL18) and cytokine (IL-10) that induce naïve CD4-positive T 
cells to become Tregs and memory TH2-like T cells. Together, these cells form a cycle of 
inhibitory immunocytes that block the function of the effector helper type I CD4-positive T-
cells (TH1-like). As a result, HPV infection is not cleared, and papillomas will recur 
(Bonagura et al., 2010). A correlation between the severity of laryngeal papillomas and an 
increase of CD83-positive dendritic cells exists, and this enhancement may be due to an 
impaired migration of matured DC (Kovalenko et al., 2009). These observations suggest that 
patients with RRP have a perturbation in their cellular immune response (or have a defect in 
their cellular immunity) and are, therefore, unable to eliminate their disease with an 
effective HPV-specific T-cell response. This immune imbalance may influence the 
development and severity of respiratory papillomatosis (Bonagura et al., 1999).  
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Fig. 8. Description of immunosuppressive mechanisms during the head and neck tumor 
progression: in the normal epithelia of the upper aerodigestive tracts, LCs are present in the 
suprabasal layers. When mucosae of these areas are exposed to tobacco, the number of LCs 
increases whereas these cells decrease in invasive carcinomas. The mature DCs are 
prominent in the peritumoral area and correlated positively with the expression of VEGF. 
DCs are also more abundant in patients with metastasis. A higher level of TAM is observed 
in HNSCCs and these cells constitute a source of VEGF which play a crucial role in 
angiogenesis. HNSCCs can induce the apoptosis of CD8+ T cells using the mitochondrial 
and/or Fas/FasL pathways. Tregs can induce apoptosis of CD8+ T cells and inhibition of 
the proliferation of CD4+ T cells. 
There are few data on the interaction between the host immune system and HPV infection in 
HNSCCs, meaning that the role of innate and adaptative immunity in the development and 
progression of HPV-positive HNSCCs is largely unknown. As mentioned previously, in 
several studies, HPV positive HNSCC cancer was associated with a favorable outcome. 
From these results, some authors supported the hypothesis that the immune response may 
play a positive role in HPV-positive HNSCC prognosis, but in those cases, an intact immune 
system is necessary. An increased frequency of T cells specific for peptides derived from the 
oncogenic HPV E7 protein was observed in HNSCC patients positive for HPV16 compared 
with HNSCC patients negative for HPV or with healthy volunteers (Albers et al., 2005; 
Hoffmann et al., 2006). Therefore, antiviral immunity exists against E7 oncogenic protein, 
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but these T cells are unable to eliminate the tumor (Hoffmann et al., 2006), perhaps due to 
immune escape of tumor cells from cytotoxic T cells (CTL) recognition (Albers et al., 2005). 
In fact, using immunohistochemistry, a reduced expression of APM components and HLA 
class I antigens was observed in HPV16-positive HNSCCs compared with adjacent normal 
squamous epithelium, which is consistent with the suggestion of a phenomenon of immune 
escape during viral carcinogenesis (Albers et al., 2005). Thus, further studies are necessary to 
explain this type of tumor resistance. Williams et al. investigated whether HPV-specific 
immune mechanisms can result in tumor clearance. For that, they generated HPV-positive 
and HPV-negative tonsil cell lines by transducing primary mouse tonsil epithelial cells, 
which are able to form squamous cell cancers in mice. When they examined immune-
competent and immune-incompetent mice with or without HPV, they observed a difference 
in growth and survival patterns. In fact, in the immune-competent mouse group, about one-
third of the HPV-positive mice cleared their tumors, compared with none of the HPV-
negative mice. Moreover, by comparing the survival of the mice that did not clear their 
tumors, they observed that mice injected with HPV-positive cells had a significantly better 
survival than mice injected with HPV-negative cells. In the mouse group lacking B- and T-
cell immunity, there was no difference in the tumor growth pattern or survival between the 
HPV-positive and HPV-negative groups. Therefore, the difference in growth between HPV-
positive and HPV-negative mice is immune mediated. The data indicated that CD4-positive 
and CD8-positive T cells were required to mount this immune response. They also showed 
that the immune clearance capacity could be transferred from a cleared mouse into an 
immunodeficient mouse. In fact, the splenocytes from cleared mice and HPV-positive tumor 
cells were injected into an immunodeficient mouse, and they observed that all treated mice 
developed and cleared tumors (Williams et al., 2009). In another animal model of HPV-
associated cancer, the authors tried to better understand why HPV-positive cancer may 
represent an advantage in survival, as has been shown in several studies, and they 
compared how these cancers responded to therapies usually used for the treatment of 
HNSCC with responses of HPV-negative tumors. Thus, they looked at the effect of radiation 
and cisplatin co-therapy on HPV-positive and HPV-negative cancer cells in vivo and in 
immunocompetent and immunodeficient mouse models. In vitro, HPV-positive cells were 
more resistant to radiation and cisplatin therapy compared with HPV-negative cells, 
whereas in vivo, HPV-positive tumors were more sensitive to radiotherapy compared with 
HPV-negative tumors. Furthermore, cisplatin was able to clear HPV-positive tumors, but 
not HPV- tumors, in mice. In immunodeficient mice, neither radiation nor cisplatin was able 
to cure their tumors. They also showed that, after an adoptive transfer of wild-type immune 
cells into immunodeficient mice, the clearance of HPV-positive tumors was restored upon 
cisplatin therapy. These findings suggested that an intact immune system was essential for 
tumor clearance with radiation and cisplatin therapy. Moreover, the findings indicate that 
survival does not seem to be due to increased epithelial sensitivity to these therapies and 
that radiation and cisplatin induce an immune response to this antigenic cancer (Spanos et 
al., 2009). More recently, Wansom and collaborators tried to understand better the clinical 
importance of adaptive immunity in patients with HPV16-positive oropharyngeal cancer 
and to examine whether it affects patient outcome. They showed that the percentage of CD8 
cells was significantly higher and the CD4:CD8 ratio was significantly lower in HPV16-
positive oropharyngeal patients. In comparing smokers and nonsmokers, the percentage of 
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CD8 cells was similar in the two groups, suggesting that the difference in CD8 levels was 
associated with HPV status and not with tobacco consumption. This elevated percentage of 
CD8 cells was associated with a response to induction chemotherapy and complete tumor 
response after chemoradiotherapy. These results (high percentage of CD8 cells and low 
CD4:CD8 ratio) were also associated with an improved overall survival. The mechanism by 
which there is an increase of T cells in the peripheral blood of HPV-positive patients has not 
been elucidated. One hypothesis suggested by the authors is that HPV-16-positive tumors 
have increased antigenicity through the E7 antigen, causing enhanced stimulation of the 
immune system, which more readily identifies tumor cells as foreign. This hypothesis is 
supported by a study led by Smith et al., in which the intralymphatic immunization of mice 
bearing E7-expressing tumors with E7 peptide resulted in a considerable expansion of E7-
specific CD8 cells, which are effective in suppressing disease progression (Smith et al., 2009). 
In another animal model, the DNA vaccine with HSP70 fused to HPV-16 E7 has been 
demonstrated to dramatically increase the frequency of E7-specific CD8-positive T cells and 
to enhance the antitumor effects against E7-expressing tumor cells (Chen et al., 2000). All of 
these data support the idea that the clearance of HPV-positive tumor cells is antigen-
dependent. Thus, the authors concluded that circulating CD8 cell levels may be a prognostic 
factor, and improved adaptive immunity may play a favorable role in the prognosis of 
patients with HPV16-positive tumors (Wansom et al., 2010). 
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